Efficacy and safety of EUS-guided hepaticoduodenostomy for unresectable malignant hilar biliary obstruction: A multicenter retrospective study using propensity score matching

Efficacy and safety of EUS-guided hepaticoduodenostomy for unresectable malignant hilar biliary obstruction: A multicenter retrospective study using propensity score matching - Efficacy and safety of EUS-guided hepaticoduodenostomy for unresectable malignant hilar biliary obstruction: A multicenter retrospective study using propensity score matching

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061426

Enrollment

270

Registered

2026-05-01

Start date

2026-03-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable malignant hilar biliary obstruction

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cohort 1(Single-arm analysis): Patients who underwent EUS-HDS for unresectable malignant hilar biliary obstruction (MHBO) between January 2015 and April 2026. Cohort 2 (Comparative analysis): Patients who underwent either EUS-HDS or EUS-HGS for unresectable MHBO between January 2015 and April 2026.

Exclusion criteria

Exclusion criteria: General exclusion criteria (for both cohorts): 1) Benign biliary strictures. 2) Malignant biliary strictures resulting from postoperative anastomotic recurrence. 3) Bismuth type I malignant hilar biliary obstruction (MHBO). Specific exclusion criteria for Cohort 2 (Comparative analysis): 1) Cases involving EUS-guided biliary drainage (EUS-BD) with bridging stenting. 2) Cases in which both EUS-HDS and EUS-HGS were performed within 14 days.

Design outcomes

Primary

Measure	Time frame
Technical success rate and clinical success rate	—

Secondary

Measure	Time frame
Adverse events (AEs), recurrent biliary obstruction (RBO), time to RBO (TRBO), re-intervention success rate, and overall survival (OS).	—

Countries

Japan

Contacts

Public ContactSoma Fukuda

National Cancer Center Hospital Department of Hepatobiliary and Pancreatic Oncology

sofukud@ncc.go.jp03-3542-2511

Outcome results